Julianna Hirsch, Itzhak Rosner, Doron Rimar, Lisa Kaly, Michael Rozenbaum, Nina Boulman, Gleb Slobodin
{"title":"托西珠单抗对一名抗CCP阳性慢性莱姆关节炎患者的疗效。","authors":"Julianna Hirsch, Itzhak Rosner, Doron Rimar, Lisa Kaly, Michael Rozenbaum, Nina Boulman, Gleb Slobodin","doi":"10.4103/1947-2714.179960","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Lyme arthritis, a manifestation of tick-borne Lyme disease, can prove to be refractory to classic treatment.</p><p><strong>Case report: </strong>We present a case of a 48-year-old male, diagnosed with chronic Lyme arthritis, refractory to recurrent and prolonged courses of doxycycline, ceftriaxone, as well as hydroxychloroquine and methotrexate. The patient responded partially to tumor necrosis factor (TNF)-alpha blockade by etanercept and, finally, entered long-term remission after his treatment was switched to tocilizumab.</p><p><strong>Conclusion: </strong>Off label treatment by biologic disease modifying antirheumatic drugs can be considered in selected patients with severe antibiotic-resistant Lyme arthritis.C.</p>","PeriodicalId":19703,"journal":{"name":"North American Journal of Medical Sciences","volume":"8 4","pages":"194-6"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866477/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tocilizumab Efficacy in a Patient with Positive Anti-CCP Chronic Lyme Arthritis.\",\"authors\":\"Julianna Hirsch, Itzhak Rosner, Doron Rimar, Lisa Kaly, Michael Rozenbaum, Nina Boulman, Gleb Slobodin\",\"doi\":\"10.4103/1947-2714.179960\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>Lyme arthritis, a manifestation of tick-borne Lyme disease, can prove to be refractory to classic treatment.</p><p><strong>Case report: </strong>We present a case of a 48-year-old male, diagnosed with chronic Lyme arthritis, refractory to recurrent and prolonged courses of doxycycline, ceftriaxone, as well as hydroxychloroquine and methotrexate. The patient responded partially to tumor necrosis factor (TNF)-alpha blockade by etanercept and, finally, entered long-term remission after his treatment was switched to tocilizumab.</p><p><strong>Conclusion: </strong>Off label treatment by biologic disease modifying antirheumatic drugs can be considered in selected patients with severe antibiotic-resistant Lyme arthritis.C.</p>\",\"PeriodicalId\":19703,\"journal\":{\"name\":\"North American Journal of Medical Sciences\",\"volume\":\"8 4\",\"pages\":\"194-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866477/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"North American Journal of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/1947-2714.179960\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"North American Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/1947-2714.179960","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tocilizumab Efficacy in a Patient with Positive Anti-CCP Chronic Lyme Arthritis.
Context: Lyme arthritis, a manifestation of tick-borne Lyme disease, can prove to be refractory to classic treatment.
Case report: We present a case of a 48-year-old male, diagnosed with chronic Lyme arthritis, refractory to recurrent and prolonged courses of doxycycline, ceftriaxone, as well as hydroxychloroquine and methotrexate. The patient responded partially to tumor necrosis factor (TNF)-alpha blockade by etanercept and, finally, entered long-term remission after his treatment was switched to tocilizumab.
Conclusion: Off label treatment by biologic disease modifying antirheumatic drugs can be considered in selected patients with severe antibiotic-resistant Lyme arthritis.C.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
